LM Gutschi, JC Malcolm, CM Favreau, TC Ooi - ANNALS OF PHARMACOTHERAPY, 2006 - Harvey Whitney Books Type 2 diabetes is a disorder characterized by insulin re- sistance with the
associated metabolic consequences of hyperglycemia, diabetic dyslipidemia,
hypertension, and hypercoagulability.1 These metabolic abnormalities ... Cited by 12 - Related articles - BL Direct - All 4 versions
C Shetty, M Balasubramani, N Capps, J … - Diabetic Medicine, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 8 - Related articles - BL Direct - All 5 versions
J Remick, H Weintraub, R Setton, J … - Cardiology in Review, 2008 - journals.lww.com Fibrates are a class of lipid-lowering medication primarily used as second-line
agents behind statins. Acting via the peroxisome proliferators-activated
receptor-α, their main lipoprotein effects are to lower serum triglyceride ... Cited by 6 - Related articles - BL Direct - All 3 versions
S Keidar, H Guttmann, T Stam, I Fishman, C … - Pharmacoepidemiology and Drug Safety, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 5 - Related articles - BL Direct - All 4 versions
CV Rizos, M Elisaf, DP Mikhailidis, EN … - Expert Opin. Drug Saf., 2009 - informahealthcare.com Background: Thiazolidinediones (TZDs) are widely used antidiabetic drugs with
proven efficacy regarding mainly surrogate markers of diabetes management.
However, efficacy on surrogate markers may not always translate into ... Cited by 5 - Related articles - All 5 versions
SA Doggrell - Expert Opin. Pharmacother., 2008 - informahealthcare.com The thiazolidinediones, rosiglitazone and pioglitazone are used in the treatment
of Type 2 diabetes (T2DM). Both have been shown to decrease glycated haemoglobin
levels, fasting plasma glucose, insulin, and free fatty acids levels in ... Cited by 4 - Related articles - BL Direct - All 7 versions
RB Goldberg, AJ Mendez - Journal of Clinical Lipidology, 2007 - Elsevier Decreased high-density lipoprotein cholesterol (HDL-C) levels have been
designated a major risk factor for cardiovascular disease, and there is
considerable interest in identifying individuals with these abnormalities ... Cited by 4 - Related articles - All 11 versions
RL Savage, A Kiuru - Diabetes care, 2005 - Am Diabetes Assoc These series of cases include only one case of HDL cholesterol lowering in a
patient taking rosiglitazone without a fibrate (1). There are no published case
reports of this reaction occurring with other thiazolidinediones, where the ... Cited by 4 - Related articles - BL Direct - All 5 versions
R Mukhtar, JPD Reckless - Diabetic medicine. Continuing education, 2005 - cat.inist.fr Dyslipidaemia in Type 2 diabetes: effects of the thiazolidinediones pioglitazone
and rosiglitazone. R MUKHTAR, JPD RECKLESS Diabetic medicine. ... Cited by 1 - Related articles - All 4 versions
D Mymin, T Dembinski, MH Friesen - The Journal of Clinical Pharmacology, 2009 - jcp.sagepub.com The authors present 5 cases of paradoxical depression of high-density
lipoprotein (HDL) cholesterol induced by fibrate drugs. In a 24-month review of
all cases seen in one physician's practice at the Winnipeg Health Sciences ... Related articles - All 5 versions
